Acura Pharmaceuticals Inc. has amended its existing loan agreement with Abuse Deterrent Pharma, LLC, as disclosed in a recent Form 8-K filing. The amendment, which involves a secured promissory note originally dated November 10, 2022, includes additional loans that extend through May 2025. The total principal amount of the loan schedule has increased to $7,994,279, with new loans added incrementally over the period. This amendment reflects Acura's ongoing financing strategy to support its operational and strategic initiatives. The agreement was signed by Robert A. Seiser, the company's Senior Vice President and CFO, on May 22, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.